{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:04:46Z","timestamp":1764889486462,"version":"3.46.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Warnings about liver dysfunction in Japanese package inserts vary among angiotensin-converting enzyme (ACE) inhibitors, and risk assessment of liver dysfunction with ACE inhibitors has been limited. To evaluate the risk of liver dysfunction among patients prescribed ACE inhibitors available in Japan, we conducted this study based on the real-world data from MID-NET\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . We identified patients who were newly prescribed ACE inhibitors between January 1, 2009 and December 31, 2019 and excluded patients with liver dysfunction before the first prescription of ACE inhibitors. To compare the risk of liver dysfunction between the control group (enalapril maleate) and each exposure group, a pairwise Cox proportional hazards model was employed to estimate the hazard ratio (HR) adjusted by inverse probability weighting based on the high-dimensional propensity score. A total of 29,817 patients were identified for analysis in the cohort. Compared with the control group, the HRs (95% confidence interval) were 1.37(0.79\u20132.38) for captopril, 0.71(0.33\u20131.54) for alacepril, 0.72(0.55\u20130.93) for imidapril hydrochloride, 1.08(0.86\u20131.34) for perindopril erbumine, and 0.69(0.52\u20130.91) for lisinopril hydrate. The risk of liver dysfunction with ACE inhibitors is unlikely to be a class-effect. Although continuous safety monitoring is necessary for promoting proper use of ACE inhibitors, the results indicate that no additional safety measures are currently required for ACE inhibitors that do not carry a liver dysfunction-related warning in Japan.\n                  <\/jats:p>","DOI":"10.1038\/s41440-025-02390-x","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:24:41Z","timestamp":1760088281000},"page":"3080-3090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET\u00ae in Japan"],"prefix":"10.1038","volume":"48","author":[{"given":"Yuki","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hotaka","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Kohama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taihei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2390_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2390_CR2","unstructured":"US - Food and Drug Administration. FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed October 22, 2024."},{"key":"2390_CR3","unstructured":"Pharmaceuticals and Medical Devices Agency. Information search for new drugs, such as review reports, package inserts, and other related infromation [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/. Accessed October 22,2024."},{"key":"2390_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Prim. 2019;5:58.","journal-title":"Nat Rev Dis Prim"},{"key":"2390_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222\u201361.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"2390_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116:878\u201398.","journal-title":"Am J Gastroenterol"},{"key":"2390_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamainternmed.2024.1833","volume":"184","author":"GY Zhang","year":"2024","unstructured":"Zhang GY, Rubin JB. Rethinking drug-induced liver injury-a new era of pharmacovigilance. JAMA Intern Med. 2024;184:952\u20133.","journal-title":"JAMA Intern Med"},{"key":"2390_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pds.4777","volume":"28","author":"K Yamada","year":"2019","unstructured":"Yamada K, Itoh M, Fujimura Y, Kimura M, Murata K, Nakashima N, et al. The utilization and challenges of Japan\u2019s MID-NET(\u00ae) medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf. 2019;28:601\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2390_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pds.4879","volume":"28","author":"M Yamaguchi","year":"2019","unstructured":"Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M, et al. Establishment of the MID-NET(\u00ae) medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf. 2019;28:1395\u2013404.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2390_CR10","unstructured":"Pharmaceuticals and Medical Devices Agency. Information for studies approved by the expert committee of MID-NET\u00ae [in Japanese]. https:\/\/www.pmda.go.jp\/files\/000238116.pdf. Accessed October 22, 2024."},{"key":"2390_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency. Act on the Pharmaceuticals and Medical Devices Agency (Act No.192 of 2002) [in Japanese]. https:\/\/laws.e-gov.go.jp\/law\/414AC0000000192. Accessed October 22, 2024."},{"key":"2390_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. Pharmacoepidemiological studies for drug safety assessment under MIHARI framework [in Japanese]. https:\/\/www.pmda.go.jp\/safety\/surveillance-analysis\/0045.html. Accessed October 22, 2024."},{"key":"2390_CR13","unstructured":"Ministry of Health Labour and Welfare. Classification of Serious Adverse Drug Reactions [in Japanese]. https:\/\/www.mhlw.go.jp\/shingi\/2005\/10\/dl\/s1006-4f2.pdf. Accessed October 22,2024."},{"key":"2390_CR14","unstructured":"Japan Clinical Oncology Group. CTCAE v5.0 grade definitions table corresponding to common standard ranges [in Japanese]. https:\/\/jcog.jp\/assets\/JCOG_kyouyoukijunchi-CTCAE_50_20210901.pdf. Accessed October 22,2024."},{"key":"2390_CR15","unstructured":"National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed October 22, 2024."},{"key":"2390_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512\u201322.","journal-title":"Epidemiology"},{"key":"2390_CR17","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/EDE.0000000000000886","volume":"29","author":"R Wyss","year":"2018","unstructured":"Wyss R, Fireman B, Rassen JA, Schneeweiss S. Erratum: high-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2018;29:e63\u2013e4.","journal-title":"Epidemiology"},{"key":"2390_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.37737\/ace.2.4_85","volume":"2","author":"M Ishimaru","year":"2020","unstructured":"Ishimaru M. Introduction to high-dimensional propensity score analysis. Ann Clin Epidemiol. 2020;2:85\u201394.","journal-title":"Ann Clin Epidemiol"},{"key":"2390_CR19","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification system https:\/\/atcddd.fhi.no\/atc_ddd_index\/ Accessed October 22,2024."},{"key":"2390_CR20","unstructured":"World Health Organization. ICD-10 : international statistical classification of diseases and related health problems : tenth revision, 2nd ed. https:\/\/apps.who.int\/iris\/handle\/10665\/42980. Accessed October 22, 2024."},{"key":"2390_CR21","unstructured":"Ministry of Health Labour and Welfare. Various Information of Medical Fee [in Japanese]. https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/. Accessed October 22,2024."},{"key":"2390_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70007","volume":"33","author":"K Kajiyama","year":"2024","unstructured":"Kajiyama K, Komamine M, Horiuchi N, Iguchi T, Uyama Y. PMDA perspective on RWD\/RWE utilization for regulatory purposes including assessment on the impacts of regulatory actions and safety risk of a drug at postmarketing stage. Pharmacoepidemiol Drug Saf. 2024;33:e70007.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2390_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"2390_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharm. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharm"},{"key":"2390_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2390_CR26","unstructured":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. LiverTox:Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Angiotensin-Converting Enzyme Inhibitors. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548912\/. Accessed October 29, 2024."},{"key":"2390_CR27","unstructured":"Organon & Co. Interview Form of RENIVACE\u00ae Tablets 2.5, 5, 10 [in Japanese]. https:\/\/organonpro.com\/ja-jp\/wp-content\/uploads\/sites\/10\/2023\/05\/if_renivace_tab.pdf. Accessed July 3,2025."},{"key":"2390_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamainternmed.2024.1836","volume":"184","author":"J Torgersen","year":"2024","unstructured":"Torgersen J, Mezochow AK, Newcomb CW, Carbonari DM, Hennessy S, Rentsch CT, et al. Severe acute liver injury after hepatotoxic medication initiation in real-world data. JAMA Intern Med. 2024;184:943\u201352.","journal-title":"JAMA Intern Med"},{"key":"2390_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/pds.3250","volume":"21","author":"JM Polinski","year":"2012","unstructured":"Polinski JM, Schneeweiss S, Glynn RJ, Lii J, Rassen JA. Confronting \u201cconfounding by health system use\u201d in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Pharmacoepidemiol Drug Saf. 2012;21:90\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2390_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.csda.2013.10.018","volume":"72","author":"JM Franklin","year":"2014","unstructured":"Franklin JM, Schneeweiss S, Polinski JM, Rassen JA. Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. Comput Stat Data Anal. 2014;72:219\u201326.","journal-title":"Comput Stat Data Anal"},{"key":"2390_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40256-023-00625-1","volume":"24","author":"ARA Rahman","year":"2024","unstructured":"Rahman ARA, Magno JDA, Cai J, Han M, Lee HY, Nair T, et al. Management of hypertension in the Asia-Pacific region: a structured review. Am J Cardiovasc Drugs. 2024;24:141\u201370.","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02390-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:45Z","timestamp":1764889305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02390-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}